Latest News & Features

Reset all filters
Article Type
Channels & Sectors
Geography
Company
Refine Search
Dr Reddy’s secures thrombosis drug rights in $17.5m deal
Asia-Pacific
Indian pharmaceutical company Dr Reddy’s has agreed a deal to buy global intellectual property rights to a generic version of GSK’s deep vein thrombosis treatment Arixtra (fondaparinux sodium) as part of a $17.5 million deal with a partner company.   27 November 2015
English High Court: Pfizer’s attempt to amend Lyrica patent an ‘abuse’ of court procedures
Big Pharma
The English High Court has rejected Pfizer’s attempt to amend a patent that was ruled partially invalid in its long-standing dispute with generics companies Mylan and Allergan.   26 November 2015
Kyle Bass targets Alpex speckled tablet patent
Americas
Hedge fund manager Kyle Bass has requested that the Patent and Trial and Appeal Board review the validity of a patent owned by Alpex Pharma.   25 November 2015
Africa
Authorities in Kenya have destroyed more than 65,000 kilos of counterfeit drugs, valued at more than KSh40 million.   25 November 2015
Americas
Pharmaceutical company Pfizer has completed a $160 billion acquisition of generics company Allergan.   23 November 2015
Americas
US law firm Merchant & Gould has hired Alireza Behrooz as a partner in the firm’s chemical and life sciences group in Washington, DC.   23 November 2015
Americas
The Federal Trade Commission has issued a final approval of Endo’s $8 billion acquisition of Par Pharmaceutical, saying it is not anti-competitive.   19 November 2015
Americas
Law firm BakerHostetler has hired Benjamin Hsing as a partner in the firm’s intellectual property group in New York.   19 November 2015
Europe
The English High Court has affirmed the validity of Eli Lilly’s European patent covering the use of the drug Strattera (atomoxetine), used to treat attention-deficit hyperactivity disorder.   18 November 2015
Big Pharma
Biopharmaceutical company Celgene has finally found success in fending off a challenge to one of its patents from Kyle Bass’s organisation the Coalition for Affordable Drugs.   17 November 2015